Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Galapagos NV - American Depositary Shares (NQ:GLPG)

33.70 +0.27 (+0.81%)
Streaming Delayed Price Updated: 2:44 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Galapagos NV - American Depositary Shares

< Previous 1 2 3 4 Next >
Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Workforce Reduction ↗
Via Stocktwits
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 23, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 23, 2025 ↗
 
Via Benzinga
News headline image
Uncovering Potential: Galapagos's Earnings Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Galapagos ↗
 
Via Benzinga
News headline image
Where Galapagos Stands With Analysts ↗
 
Via Benzinga
News headline image
Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed ↗
The company expects to announce a new CFO “in the coming months.” 
Via Stocktwits
Topics Earnings
News headline image
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus ↗
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline. 
Via Benzinga
News headline image
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' ↗
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T... 
Via Benzinga
News headline image
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
News headline image
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade ↗
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,... 
Via Benzinga
News headline image
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024 ↗
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 ↗
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst ↗
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
News headline image
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments ↗
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG). 
Via Benzinga
News headline image
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023 ↗
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.